NewAmsterdam Pharma Co N.V. Annual Operating Income (Loss) in USD from 2021 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
NewAmsterdam Pharma Co N.V. quarterly/annual Operating Income (Loss) history and growth rate from 2021 to 2023.
  • NewAmsterdam Pharma Co N.V. Operating Income (Loss) for the quarter ending September 30, 2024 was -$25M, a 49.5% increase year-over-year.
  • NewAmsterdam Pharma Co N.V. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$184M.
  • NewAmsterdam Pharma Co N.V. annual Operating Income (Loss) for 2023 was -$183M, a 5044% decline from 2022.
  • NewAmsterdam Pharma Co N.V. annual Operating Income (Loss) for 2022 was -$3.56M, a 89.8% increase from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$183M -$179M -5044% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-28
2022 -$3.56M +$31.4M +89.8% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-28
2021 -$35M Jan 1, 2021 Dec 31, 2021 10-K 2024-02-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.